Guy A Higgins1,2, Leo B Silenieks3, Everett B Altherr4, Cam MacMillan5, Paul J Fletcher6,7,8, Wayne E Pratt4. 1. InterVivo Solutions Inc., 120 Carlton Street, Toronto, ON, M5A 4K2, Canada. guyh@intervivo.com. 2. Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, M5S 4K2, Canada. guyh@intervivo.com. 3. InterVivo Solutions Inc., 120 Carlton Street, Toronto, ON, M5A 4K2, Canada. 4. Department of Psychology, Wake Forest University, Winston-Salem, NC, 27109, USA. 5. Vivocore, 120 Carlton Street, Toronto, ON, M5A 4K2, Canada. 6. Department of Psychiatry, University of Toronto, Toronto, ON, M5T 1R8, Canada. 7. Department of Psychology, University of Toronto, Toronto, ON, M5S 3G3, Canada. 8. Centre for Addiction and Mental Health, 250 College Street, Toronto, ON, M5T 1R8, Canada.
Abstract
RATIONALE: The 5-HT2C receptor agonist lorcaserin (Belviq®) has been approved by the FDA for the treatment of obesity. Impulsivity is a contributory feature of some eating disorders. OBJECTIVE: Experiments investigated the effect of lorcaserin and the highly selective 5-HT2C agonist CP-809101 on measures of impulsivity and on reinstatement of food-seeking behaviour, a model of dietary relapse. The effect of both drugs on 22-h deprivation-induced feeding was also examined, as was the effect of prefeeding in each impulsivity test. RESULTS: Lorcaserin (0.3-0.6 mg/kg SC) and CP-809101 (0.6-1 mg/kg SC) reduced premature responding in rats trained on the 5-CSRTT and improved accuracy in a Go-NoGo task by reducing false alarms. At equivalent doses, both drugs also reduced reinstatement for food-seeking behaviour. Neither drug altered impulsive choice measured in a delay-discounting task. Lorcaserin (1-3 mg/kg SC) and CP-809101 (3-6 mg/kg SC) reduced deprivation-induced feeding but only at higher doses. CONCLUSIONS: These results suggest that in addition to previously reported effects on satiety and reward, altered impulse control may represent a contributory factor to the anti-obesity property of 5-HT2C receptor agonists. Lorcaserin may promote weight loss by improving adherence to dietary regimens in individuals otherwise prone to relapse and may be beneficial in cases where obesity is associated with eating disorders tied to impulsive traits, such as binge eating disorder.
RATIONALE: The 5-HT2C receptor agonist lorcaserin (Belviq®) has been approved by the FDA for the treatment of obesity. Impulsivity is a contributory feature of some eating disorders. OBJECTIVE: Experiments investigated the effect of lorcaserin and the highly selective 5-HT2C agonist CP-809101 on measures of impulsivity and on reinstatement of food-seeking behaviour, a model of dietary relapse. The effect of both drugs on 22-h deprivation-induced feeding was also examined, as was the effect of prefeeding in each impulsivity test. RESULTS:Lorcaserin (0.3-0.6 mg/kg SC) and CP-809101 (0.6-1 mg/kg SC) reduced premature responding in rats trained on the 5-CSRTT and improved accuracy in a Go-NoGo task by reducing false alarms. At equivalent doses, both drugs also reduced reinstatement for food-seeking behaviour. Neither drug altered impulsive choice measured in a delay-discounting task. Lorcaserin (1-3 mg/kg SC) and CP-809101 (3-6 mg/kg SC) reduced deprivation-induced feeding but only at higher doses. CONCLUSIONS: These results suggest that in addition to previously reported effects on satiety and reward, altered impulse control may represent a contributory factor to the anti-obesity property of 5-HT2C receptor agonists. Lorcaserin may promote weight loss by improving adherence to dietary regimens in individuals otherwise prone to relapse and may be beneficial in cases where obesity is associated with eating disorders tied to impulsive traits, such as binge eating disorder.
Authors: Guy A Higgins; Leo B Silenieks; Anne Rossmann; Zoe Rizos; Kevin Noble; Ashlie D Soko; Paul J Fletcher Journal: Neuropsychopharmacology Date: 2011-12-21 Impact factor: 7.853
Authors: Guy A Higgins; Jill Desnoyer; Annalise Van Niekerk; Leo B Silenieks; Winnie Lau; Sandy Thevarkunnel; Julia Izhakova; Ines Am DeLannoy; Paul J Fletcher; Josepha DeLay; Howard Dobson Journal: Pharmacol Res Perspect Date: 2014-11-07
Authors: Clara Velázquez-Sánchez; Antonio Ferragud; Catherine F Moore; Barry J Everitt; Valentina Sabino; Pietro Cottone Journal: Neuropsychopharmacology Date: 2014-04-29 Impact factor: 7.853
Authors: Leigh V Panlilio; Maria E Secci; Charles W Schindler; Charles W Bradberry Journal: Psychopharmacology (Berl) Date: 2017-09-04 Impact factor: 4.530
Authors: Wayne E Pratt; Rafaella Vaca-Tricerri; Alexa C Blanchard; Thomas R Hopkins; Adeolu O Ilesanmi; Zachary Pierce-Messick; Ian A Rosner; Rose Ying Journal: Behav Brain Res Date: 2021-01-23 Impact factor: 3.332
Authors: Michelle M Rodriguez; Carl Overshiner; J David Leander; Xia Li; Denise Morrow; Richard G Conway; David L Nelson; Karin Briner; Jeffrey M Witkin Journal: Front Psychiatry Date: 2017-05-22 Impact factor: 4.157
Authors: Giuseppe Di Giovanni; Rahul Bharatiya; Emilie Puginier; Marta Ramos; Salomé De Deurwaerdère; Abdeslam Chagraoui; Philippe De Deurwaerdère Journal: Front Pharmacol Date: 2020-06-30 Impact factor: 5.810
Authors: Sade E Johns; Lori Keyser-Marcus; Antonio Abbate; Edward Boone; Benjamin Van Tassell; Kathryn A Cunningham; Noelle C Anastasio; Justin L Poklis; Tatiana Ramey; F Gerard Moeller Journal: Front Psychiatry Date: 2021-07-02 Impact factor: 4.157